Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients

被引：7
|
作者：
Julian, K. G. [1 ]
Shattahi, E. [1 ]
Burg, J. E. [2 ]
Boehmer, J. P. [2 ]
机构：
[1] Penn State Hershey Med Ctr, Div Infect Dis, Hershey, PA 17033 USA
[2] Penn State Hershey Med Ctr, Div Cardiol, Hershey, PA 17033 USA
来源：
TRANSPLANTATION PROCEEDINGS | 2013年 / 45卷 / 09期
关键词：
ORAL GANCICLOVIR; DISEASE; PREVENTION; EFFICACY; SAFETY;
D O I：
10.1016/j.transproceed.2013.08.023
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving lowdose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2%) of the 18 D+/R- patients and 1 (2.7%) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/mu L] that occurred in 21.8% and severe neutropenia (ANC <500 cells/ILL) in 7.3%. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.
引用
收藏
页码：3414 / 3417
页数：4
相关论文
共 50 条
  • [1] Does Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis Affect Outcomes in Kidney Transplant Recipients?
    Gillespie, M.
    Smith, L.
    Lee, S.
    Kenyon, N.
    Truax, C.
    Corbett, J.
    Shihab, F.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 322 - 322
  • [2] Safety and Effectiveness of Low-Dose Cytomegalovirus Valganciclovir Prophylaxis in CMV Seropositive Lung Transplant Recipients
    Lehikoinen, R. A.
    Syrjala, S.
    Heliovaara, E.
    Tikkanen, J.
    Lemstrom, K.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S486 - S486
  • [3] Risk Assessment of Neutropenia during Low-Dose Valganciclovir Prophylaxis for Heart Transplant Recipients
    Otokubo, Mai
    Wada, Kyoichi
    Ikura, Megumi
    Hayase, Kotoka
    Uno, Takaya
    Nakagita, Kazuki
    Hayakawa, Naoki
    Watanabe, Takuya
    Seguchi, Osamu
    Fukushima, Norihide
    Nakamura, Tsutomu
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (04) : 452 - 459
  • [4] Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients
    Dupuis, R.
    Harris, M.
    Gillis, K.
    Gerber, D.
    Fair, J.
    Watson, R.
    Koslowski, T.
    Andreoni, K.
    [J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (10) : 3266 - 3270
  • [5] Efficacy and safety of low-dose valganciclovir prophylaxis among renal transplant recipients
    Sayilar, Emel Isiktas
    Ergun, Ihsan
    [J]. CUKUROVA MEDICAL JOURNAL, 2020, 45 (01): : 347 - 351
  • [6] Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients
    Khan, Salman
    Sullivan, Timothy
    Ali, Mohsin
    Dunn, Dallas
    Patel, Gopi
    Huprikar, Shirish
    [J]. LIVER TRANSPLANTATION, 2018, 24 (05) : 616 - 622
  • [7] Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients
    Li, Yihan
    Pluckrose, Dawn M.
    Patolia, Roshani
    Arnouk, Serena
    Dubrovskaya, Yanina
    Papadopoulos, John
    Jonchhe, Srijana
    [J]. ANNALS OF PHARMACOTHERAPY, 2024,
  • [8] Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients
    Park, Jeong M.
    Lake, Kathleen D.
    Fontana, Robert J.
    [J]. LIVER TRANSPLANTATION, 2006, 12 (06) : 1022 - 1023
  • [9] African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
    Patel, S.
    Kuten, S.
    Loucks-DeVos, J.
    Knight, R.
    Gaber, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [10] Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Bixby, Alexandra L.
    Fitzgerald, Linda
    Park, Jeong M.
    Kaul, Daniel
    Tischer, Sarah
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
12345